Alan B Lancz & Associates Inc. Has $930,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Alan B Lancz & Associates Inc. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 11,090 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the period. Gilead Sciences accounts for about 0.9% of Alan B Lancz & Associates Inc.’s holdings, making the stock its 28th biggest position. Alan B Lancz & Associates Inc.’s holdings in Gilead Sciences were worth $930,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GILD. Manning & Napier Advisors LLC purchased a new position in Gilead Sciences in the second quarter valued at about $25,328,000. Legal & General Group Plc lifted its holdings in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after buying an additional 93,068 shares during the last quarter. IRON Financial LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $830,000. GSA Capital Partners LLP acquired a new position in Gilead Sciences in the first quarter worth approximately $462,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in Gilead Sciences by 13.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after acquiring an additional 33,162 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,437 shares of company stock valued at $5,374,825 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday. Robert W. Baird boosted their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday. Barclays increased their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, BMO Capital Markets boosted their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $91.50.

Gilead Sciences Stock Down 1.4 %

Shares of GILD opened at $96.57 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The company has a 50-day simple moving average of $85.30 and a 200-day simple moving average of $75.03. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.32. The firm has a market capitalization of $120.22 billion, a P/E ratio of 1,072.94, a P/E/G ratio of 3.19 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 28.60% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.76 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.19%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.